Now showing items 1-1 of 1
Screening for calreticulin mutations in a cohort of patients suspected of having a myeloproliferative neoplasm
(Health and Medical Publishing Group (HMPG), 2016)
Background. The discovery of calreticulin (CALR) has shown it to be the second most frequent mutation after the Janus Kinase 2 (JAK2) mutation in myeloproliferative neoplasms (MPNs). Its structure indicates various ...